This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
29 Apr 2011

J&J's Prostate Cancer Drug Zytiga Approved by FDA

The FDA has approved Zytiga in combination with prednisone for patients with late-stage castration-resistant prostate cancer.

Johnson & Johnson's buyout of Cougar Biotech has paid off. The FDA has approved Zytiga (abiraterone acetate) in combination with prednisone for patients with late-stage castration-resistant prostate cancer who have previously received chemotherapy.

 

In clinical trials, those who received Zytiga and prednisone had a median overall survival of 14.8 months compared to 10.9 months for patients receiving the placebo and prednisone, according to a statement. The decision comes almost two months ahead of the June 20 deadline.

 

J&J i

Related News